BIOMARKER:

ROS1 rearrangement

Entrez ID:

Related biomarkers:

‹

›

ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: A2 - Guideline	ceritinib Sensitive: A2 - Guideline
ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A2 - Guideline	lorlatinib Sensitive: A2 - Guideline
ROS1 rearrangement ROS1 rearrangement	Lung Cancer Lung Cancer	ROS1 rearrangement ROS1 rearrangement	Lung Cancer Lung Cancer	crizotinib Sensitive: C2 – Inclusion Criteria	crizotinib Sensitive: C2 – Inclusion Criteria
ROS1 rearrangement ROS1 rearrangement	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ROS1 rearrangement ROS1 rearrangement	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	crizotinib Sensitive: C2 – Inclusion Criteria	crizotinib Sensitive: C2 – Inclusion Criteria
ROS1 rearrangement ROS1 rearrangement	Lung Adenocarcinoma LUAD	ROS1 rearrangement ROS1 rearrangement	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C3 – Early Trials	crizotinib Sensitive: C3 – Early Trials
ROS1 rearrangement ROS1 rearrangement	Lung Adenocarcinoma LUAD	ROS1 rearrangement ROS1 rearrangement	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: C3 – Early Trials	brigatinib Sensitive: C3 – Early Trials
ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
ROS1 rearrangement ROS1 rearrangement	Lung Adenocarcinoma LUAD	ROS1 rearrangement ROS1 rearrangement	Lung Adenocarcinoma LUAD	ceritinib Sensitive: C4 – Case Studies	ceritinib Sensitive: C4 – Case Studies